As MEK is activated in tumours in which MAP3K8 accumulates (see below), we confirmed the impact of MAP3K8/MEK on patient response to treatment in partially resected HGSC by analysing MEK phosphorylation in the The Cancer Genome Atlas (TCGA) database (Supplementary Fig. 1E). This evidence concerns the gene MAP3K8 and neoplasm.